Joshua Slatko

2 months ago | pharmalive.com | Joshua Slatko

Agenda 2025: A new frontierWith a new administration in Washington, new AI and data tools, new approaches to omnichannel communications, and new ways to target and engage HCPs and patients at ever more granular levels, 2025 in pharma seems likely to look very much unlike what’s come before. By Joshua Slatko | [email protected]In the pharma world, 2024 seems so 1990, even though it ended just a few months ago.

Dec 9, 2024 | pharmalive.com | Joshua Slatko

Ad-ventures in Marketing XVIIFor the seventeenth year, Med Ad News has chosen a group of new Pharmaceutical Marketing Ventures to Watch that could change the way pharmaceutical products are marketed and sold. By Joshua Slatko | [email protected]This past October, the Med Ad News team began its annual search for the future of pharmaceutical marketing.

Oct 10, 2024 | pharmalive.com | Joshua Slatko

Despite the decline of its COVID treatment, Gilead has managed to keep the top line stable for three consecutive years. By Joshua Slatko • Gilead Sciences333 Lakeside DriveFoster City, CA 94404650-574-3000 • gilead.comFinancial Performance202320221H 20241H 2023Revenue$27,116$27,281$13,640 $12,951Net income$5,613$4,566$2,556$2,024Diluted EPS$4.50$3.64$2.05$1.63R&D expense$5,718$4,977$2,871$2,854All figures are in millions of dollars, except EPS.

Oct 10, 2024 | pharmalive.com | Joshua Slatko

Lilly’s tirzepatide caught the public’s attention in 2023, and a whole lot of dollars, too. By Joshua Slatko • Eli LillyLilly Corporate CenterIndianapolis, IN 46285317-276-2000 • lilly.comFinancial Performance202320221H 20241H 2023Revenue$34,124$28,541$20,071$15,272Net income$5,240$6,245$5,210$3,108Diluted EPS$5.80$6.90$5.76$3.44R&D expense$9,313$7,191$5,234$4,342All figures are in millions of dollars, except EPS. Best-selling productsAll sales are in millions of dollars.

Oct 10, 2024 | pharmalive.com | Joshua Slatko

With $25 billion in sales last year and 41 approvals so far in the United States alone, Merck’s multidimensional oncologic is now the world’s best-selling prescription drug. By Joshua Slatko • Merck126 East Lincoln AvenueRahway, NJ 07065908-740-4000 • merck.comFinancial Performance202320221H 20241H 2023Revenue$60,115$59,283$31,887$29,522Net income$365$14,519$10,228-$3,147Diluted EPS$0.14$5.71$4.02-$1.24R&D expense$30,531$13,548$7,492 $17,597All figures are in millions of dollars, except EPS.